Session Detail


Oral
O1-02.Advances in PET Amyloid Imaging.
Sunday, Jul 11, 2010, 1:00 PM - 3:00 PM
Hall 1
Chairs:
Christopher M. Clark, MD.
Avid Radiopharmaceuticals, Philadelphia, PA, USA.
Reisa Sperling, M.D..
Brigham and Women's Hospital, Boston, MA, USA.
Presentations:
7/11/2010 1:00:00 PM
O1-02-01. Florbetaben for β-amyloid brain PET in Alzheimer disease - Results of a multicentre phase 2 trial
Osama Sabri1, Hermann-Josef Gertz1, Stefan Dresel2, Isabella Heuser3, Peter Bartenstein4, Katharina Bürger4, Florian Hiemeyer5, Cornelia Reininger5, John Seibyl6, Henryk Barthel1.
1University of Leipzig, Leipzig, Germany, 2Helios Hospital Berlin-Buch, Berlin, Germany, 3Charite-Campus Benjamin Franklin, Berlin, Germany, 4Ludwig-Maximilian University Munich, Munich, Germany, 5Bayer Healthcare, Berlin, Germany, 6MNI, New Haven, CT, USA.

7/11/2010 1:15:00 PM
O1-02-02. 18F-Florbetaben-PET imaging in the differential diagnosis of dementia
Victor L. Villemagne, MD1,2, Kevin Ong, MD1, Narelle Langdon, RN1, Gerhard Holl, MD3, Cornelia Reininger, MD3, Barbara Putz, PhD3, Gareth Jones1, Thomas Dyrks, PhD3, Ludger Dinkelborg, PhD3, Uwe Ackermann, PhD1, Rachel Mulligan, PhD1, Graeme O'Keefe, PhD1, Beate Rohde, PhD3, Colin L. Masters, MD2, Christopher Rowe, MD1.
1Austin Hospital, Melbourne, VIC, Australia, 2The Mental Health Research Institute, Melbourne, VIC, Australia, 3Bayer Schering Pharma, Berlin, Germany.

7/11/2010 1:30:00 PM
O1-02-03. Phase III Trial Results for the Amyoid PET Imaging Agent Florbetapir F 18 (18F-AV-45): Imaging to histopathologic correlations in an end of life human subject study
Christopher M. Clark, MD1, Julie A. Schneider, MD2, Mark M. A. Mintun, MD3, Barry J. Bedell, MD, PhD4, Thomas G. Beach, MD, PhD5, Carl H. Sadowsky, MD6, P M. Doraiswamy, MD7, Jose Gamez, MD8, Marwan N. Sabbagh, MD9, Adam S. Fleisher, MD10, Frederick Schaerf, MD, PhD11, Malika Waseem, MD12, Michael J. Pontecorvo, PhD1, Franz F. Hefti, PhD1, Daniel M. Skovronsky, MD, PhD1, AV45-A07 Study Group.
1Avid Radiopharmaceuticals, Philadelphia, PA, USA, 2Rush University, Chicago, IL, USA, 3Washington University, St. Louis, MO, USA, 4Biospective Inc., Montreal, QC, Canada, 5Sun Health Research Institute, Sun City, AZ, USA, 6Nova SE University, Ft. Lauderdale, FL, USA, 7Duke University Medical Center, Durham, NC, USA, 8Galiz Research, Miami, FL, USA, 9Banner Sun Health Research Institute, Sun City, AZ, USA, 10Banner Alzheimer’s Institute, Phoenix, AZ, USA, 11Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, FL, USA, 12Waseem, Exon, MD, USA.

7/11/2010 1:45:00 PM
O1-02-04. Florbetapir F 18 (18F-AV-45) PET amyloid imaging predicts progression of cognitive impairment: A longitudinal clinical follow up study.
Reisa A. Sperling, M.D.1,2, P Murali Doraiswamy, MD3, Keith Johnson, M.D.1, Eric M. Reiman, MD4, Marwan N. Sabbagh, M.D.5, Carl H. Sadowsky, M.D.6,7, Alan Carpenter, Ph.D.8, Chris M. Clark, M.D.8, Mathew Flitter8, Michael J. Pontecorvo, Ph.D.8, Daniel M. Skovronsky, M.D.8.
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA, 3Duke University Medical Center, Durham, NC, USA, 4Banner Alzheimer's Institute, Phoenix, AZ, USA, 5Banner-Sun Health Research Institute, Sun City, AZ, USA, 6Premire Research Institute, West Palm Beach, FL, USA, 7Nova SE University, Fort Lauderdale, FL, USA, 8Avid Radiopharmaceuticals, Philadelphia, PA, USA.

7/11/2010 2:00:00 PM
O1-02-05. Concordance between visual read and quantification for categorisation of [18F]flutemetamol data into either normal or abnormal amyloid levels
Lennart Thurfjell, PhD1, Chris J. Buckley, PhD2, Rikard Owenius, PhD1, Gill Farrar, PhD2, David J. Brooks, MD, DSc3, Rik Vandenberghe, MD4, Koen Van Laere, MD4, Eric Salmon, MD5, Ian Law, MD6, Gunhild Waldemar, MD6.
1GE Healthcare, Uppsala, Sweden, 2GE Healthcare, Amersham, United Kingdom, 3GE Healthcare and Imperial College London, London, United Kingdom, 4KU Leuven, Leuven, Belgium, 5CRC/ University of Liege, Liege, Belgium, 6Rigshospitalet, Copenhagen, Denmark.

7/11/2010 2:15:00 PM
O1-02-06. First ever longitudinal [11C]PIB and [18f]FDDNP PET studies in patients with Alzheimer's disease, mild cognitive impairment and healthy controls.
Rik Ossenkoppele, Nelleke Tolboom, Jessica Foster-Dingley, Ronald Boellaard, Maqsood Yaqub, Albert D. Windhorst, Wiesje M. van der Flier, Frederik Barkhof, Adriaan A. Lammertsma, Philip Scheltens, Bart N.M. van Berckel.
VU University Medical Centre, Amsterdam, Netherlands.

7/11/2010 2:30:00 PM
O1-02-07. Relationship of fibrillar amyloid-beta burden with age-at-onset in Alzheimer’s disease
IL HAN CHOO, MD, PhD1, Dong Young Lee, MD, PhD1, Jee Wook Kim, MD1, Eun Hyun Seo, MS2, Dong Soo Lee, MD, PhD3, Yu Kyung Kim, MD, PhD4, Ki Woong Kim, MD, PhD5, Jong Inn Woo, MD, PhD1.
1Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea, Republic of, 2Clinical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, 3Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, 4Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, 5Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of.

7/11/2010 2:45:00 PM
O1-02-08. Transforming CSF Aβ42 measures of brain Aβ amyloid into calculated PIB (PIBcalc) units
Clifford R. Jack, Jr., M. D.1, Stephen D. Weigand, M.S.1, Prashanthi Vemuri, Ph.D.1, Heather J. Wiste1, Paul S. Aisen, M.D.2, Ronald C. Petersen, M.D., Ph.D.1, Michael W. Weiner, M.D.3, David S. Knopman, M.D.1, Leslie M. Shaw, Ph.D.4, John Q. Trojanowski, Ph.D.4.
1Mayo Clinic, Rochester, MN, USA, 2University of California at San Diego, LaJolla, CA, USA, 3University of California at San Francisco, San Francisco, CA, USA, 4University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

 

Technical Support
Phone: 217-398-1792
Helpdesk